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Pure ground glass opacities (GGO) may indicate pre-invasive subtypes of lung carcinoma. These neoplasms
typically demonstrate indolent patterns of growth; Fleischner Society guidelines recommend up to five years of
serial imaging. Our aim was to determine the frequency of diagnosed carcinoma arising from GGO detected
beyond 5 years of surveillance. We reviewed pathologic diagnoses of lung carcinoma (n = 442) between 2016
and 2018 of a tertiary academic hospital and National Cancer Institute-designated cancer center to identify all
cancers that arose from ground glass opacities detected on CT scan. Of the 442 cases of lung carcinoma, 32 (7%)
were found that arose from pure GGOs and were ultimately diagnosed as cancer. Among the subgroup of GGOs,
78% (n = 25) were diagnosed within five years of surveillance, but up to 22% (n = 7) required between five and
twelve years of serial follow up prior to definitive diagnosis. In order to detect 95% of cancers, GGOs would need
to be followed for 7.9–12.7 years based upon a Kaplan-Meier estimate (p = 0.05). No patients who had lung
carcinoma arising from GGOs died (0/32) within a follow-up time of one to three years. These data suggest that a
greater number of lung carcinomas would be detected upon routine follow up of GGOs that extended beyond the
current recommendation of five years. The overall survival of the cohort was 100%, consistent with existing data
that these cancers are indolent. It is unknown whether a higher detection rate from longer interval follow up
would impact overall survival.

1. Introduction

a change in size of lung nodules may evade detection in lesions that are
slow growing [11,12].

Pure ground glass opacities (GGOs) are radiological findings on
computed tomography (CT) of the chest that are described as hazy
increased opacity of the lung with no solid, or entirely opaque compo
nents that obscure the underlying vessels ([1], Fig. 1). These may be a
result of an inflammatory process but may also be a precursor of carci
noma of the lung [2,3]. It is commonly accepted that solid or subsolid
nodules hold an increased risk of malignancy when compared with pure
GGOs [4,5]. Current guidelines for the protocol of managing findings of
GGOs on CT are based on the updated Fleischner Society 2017 guide
lines [6]. Fleischner Guidelines are challenged by more recent research
that suggest more extensive follow up may be required to identify po
tential cancers [7]. These more recent studies for suspicious lesions less
than 6 mm, call for a single follow up within two to four years. For le
sions 6–8 mm, follow up in six to twelve months was recommended with
sequential follow up every two years [8–10]. These authors followed
patients for 3.5 years, so their conclusions may be incomplete and
require more extensive follow up because it has been demonstrated that

2. Materials and methods
Electronic medical records were reviewed from Thomas Jefferson
University Hospital, a quaternary care center and teaching hospital for
the Sidney Kimmel Cancer Center, a National Cancer Institutedesignated cancer center. Cases of pathologically confirmed lung car
cinoma between April 2016 and April 2018 (a two-year interval) were
identified. The study was approved by the Institutional Review Board
(IRB). A waiver of informed consent was requested and approved by the
IRB.
Of the 442 carcinomas identified, we searched imaging reports to
discern cancers that were initially identified as pure GGOs. The resulting
32 reports were manually examined to identify the time between initial
GGO finding on CT and ultimate time to diagnosis of cancer. For all 32
patients we identified demographic data, reviewed imaging character
istics, noted intervention and recorded survival outcomes. Any previous

* Corresponding author.
E-mail address: gregory.kane@jefferson.edu (G. Kane).
https://doi.org/10.1016/j.rmed.2022.106803
Received 22 June 2021; Received in revised form 19 February 2022; Accepted 2 March 2022
Available online 12 March 2022
0954-6111/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

E. Herskovitz et al.

Respiratory Medicine 196 (2022) 106803

7) required between five and twelve years of serial follow up prior to
definitive diagnosis. (Figs. 2 and 3). While many patients were followed
with repeat CT over time, the majority had minimal or no change. Of the
group that was diagnosed after five years (n = 7), 29% (or 2 of these 7
patients) evolved from GGO to part-solid nodules between the first and
last CT performed before carcinoma was detected and 5 remained
ground glass for the entire period of observation. Forty three percent (3
of 7 patients) had a 2 mm or less change within 5 years. Of the remaining
4, one did not have a data point near the five-year mark. For subjects 5
and 6, change was not detected until 66 months (greater than 5 years).
The nodules remained ground glass at the five-year mark. Data sum
marized in Table 1.
Of the caners that had minimal change, the reason for follow up CT
varied from provider preference, another indication for chest imaging,
and patient request. Of those 7 cancers, 4 qualified for LCS.
In order to detect 95% of cancers that are initially identified as GGOs,
they would need to be followed for at least 7.9–12.7 years based upon a
Kaplan-Meier estimate for time to diagnosis (p = 0.05).
Fig. 1. Original CT Image shows smoothly marginated lung nodule with visu
alization of the underlying vessels consistent with ground glass opacity.

4. Discussion
Current guidelines suggest follow-up on GGO found on CT inciden
tally or otherwise for at least five years [6]. In our cohort of patients 23%
(7 of 32) were diagnosed with carcinoma and found to be initially
detected as GGO.
In this series of patients with carcinoma arising as GGO, several were
followed for extensive time frames yet none of the patients died during
the period of radiographic follow up or one to three years of observation
after definitive therapy. This suggests the possibility that these carci
nomas are quite indolent may not require surgical intervention to assure
favorable patient outcomes. Thus, a criticism of our work would be that
outcome may not necessarily be improved from longer periods of
observation. Nonetheless, the identification of indolent carcinomas well
beyond five years is an important observation for investigators and
public health professionals. Further prospective trials of expanded
populations in multiple centers could help provide further guidance for
these challenging management questions.
It is important to acknowledge that patients included in this study
were not being managed under any particular protocol. Some were
followed outside of this referral based urban academic center, others
were managed by academic pulmonologists and academic thoracic
surgeons outside of any clinical trial. Critics might conclude that lesions
resected beyond 5 years and up to 12 years after detection should have
been resected earlier. We believe, however, that outcomes of care by
experienced clinicians working in the academic environment, represent
a typical approach to patient management that may well reflect the
experience across the country. Some of the reported cases were lost to

CT scans were analyzed for subtle GGOs that may have been overlooked
on initial read.
The CT results were evaluated for the initial size and characteristics
of the lesions as well as those of the subsequent findings, in such cases
where follow-up did occur. In some patients, the lesion changed over
time and this was recorded. The clinical characteristics that were
examined over time included size, location and attenuation (i.e. solid,
subsolid or pure ground glass). Patient demographics were also noted
including patient age, sex, race, ethnicity, comorbid conditions and
smoking status.
We performed a retrospective cohort study Kaplan Meier analysis to
describe the average time to diagnosis. Additionally, confidence in
tervals of the Kaplan Meier analysis were calculated to determine length
of follow-up that would ensure identifying transformation to carcinomas
in 95% of cases that begin as GGOs.
3. Results
Out of the 32 patients with carcinomas in the lung that began as an
isolated GGO, 66% (n = 21) were females and 34% (n = 11) were males.
The average age was 76 ± 9 years. Of the 32 participants 17% (n = 7)
were active smokers, 59% (n = 19) were former smokers and 19% (n =
6) were never smokers at the time of diagnosis. 75% (n = 23) of patients
with carcinoma qualified for lung cancer screening (LCS). None of the
study participants died within a follow up of one to three years.
Among the subgroup of GGOs, 78% (n = 25) were diagnosed with
lung carcinoma within the first five years of surveillance, but 22% (n =

Fig. 2. Kaplan meier linear regression for time to diagnosis.

Fig. 3. Lag time to diagnosis bar chart.
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Table 1
Summarization of records of patients in which diagnosis was greater than five years after initial diagnosis. Including subject number, date of diagnosis, and diagnostic
modality.
Subject Date of
initial
detection of
ground
glass
opacity

Diameter
Date of
at the time pathologic
of
diagnosis
diagnosis

Diameter at
the time of
pathological
diagnosis

Difference
in time in
months

Difference in
largest diameter
between initial
diagnosis and
pathological
diagnosis

Difference in
diameter
between initial
diagnosis and
scan closest to,
but after the 5year mark.

Radiologic
description
of most
recent CT
report

Diagnostic
modality

Detail of the pathology Cancer
report
Stage

1

06–2010

13 mm

03–2018

20 mm

93 mo

7 mm

0 mm

Part solid

Surgical

2

06–2007

21 mm

09–2017

30 mm

123 mo

9 mm

1 mm

Part solid

Surgical

3

11–2005

13 mm

06–2017

30 mm

139 mo

17 mm

2 mma

Ground glass

Surgical

Invasive
adenocarcinoma,
acinar predominant
Invasive
adenocarcinoma,
acinar predominant
Bronchioalveolar
adenocarcinoma
Adenocarcinoma

b

4

08–2007

25 mm

07–2016

29 mm

107 mo

4 mm

N/A

Ground glass

5

03–2011

23 mm

09–2016

30 mm

66 mo

7 mm

3 mm

Ground glass

CT-guided
biopsy
Surgery

6

03–2010

10 mm

10–2016

15 mm

80 mo

5 mm

4 mm

Ground glass

Surgery

02–2011

10 mm

08–2016

15 mm

66 mo

5 mm

5 mm

Ground glass

Bronchoscopy

7
a
b

Adenocarcinoma
mixed subtype
Multiple synchronous
primary tumors:
acinar
adenocarcinoma,
squamous cell
carcinoma and
broncho vascular
carcinoma
Adenocarcinoma

IA3
IA
IA
IV
IB
IA

IA

Patient lost to follow-up after five-year scan, but returned with nodule increase in length.
No scan at 5-year mark, closest scan is at 3 years, with 1 mm change in diameter. The next scan is at 7 years with 3 mm change.

cohort was 100% (with one to three years of follow-up) consistent with
existing data that these cancers are indolent. It is unknown whether a
higher detection rate would impact overall survival. More extended
observation time and a prospective approach are required for confir
mation of our findings.
Of the 7 patients who had carcinoma detected between five and 12
years, several featured radiological reports had reported that the ground
glass was stable when comparing to previous image. These reports did
not comment on scans dating back to initial detection. This suggests that
the standard for following nodules should routinely include comparison
not only to the most prior image but to the index image when the lesion
was initially identified [14]. As such a more definitive appraisal of
nodule growth can be reported to the clinician.
While 5 of those 7 patients with cancer would have qualified for LCS
if project retrospectively, the uptake nationally for LCS has been slow
and the majority of the cancers were initially identified well before LCS
was recommended [15].
This small case series from one urban academic center does not
address several practical implications of extending the period of obser
vation of GGOs. These practical considerations include the likelihood of
increased numbers of patients who may be lost to follow-up during in
tervals of subsequent imaging that extend between two to five years.
Furthermore, the cost benefit of extending observation for these com
mon lesions has not been considered and should certainly be studied
prior to any formal change in the current management guidelines. With
no deaths in our cohort of 32 carcinomas which began as GGOs it would
be impossible to calculate life years saved on the basis of screening and
this should be considered prior to any formal change in the guidelines.
Perhaps like many patients with prostate cancer, patients might die
with pulmonary carcinoma arising from GGOs rather than die from
pulmonary carcinoma arising from GGOs. Thus, in patients whose sur
vival is determined by other diagnoses or co-morbid conditions,
continued follow up or intervention upon these lesions is probably not
necessary. Still, in several patients with delayed diagnosis aggressive
and invasive cancers were noted on the pathology report.

follow-up but returned with further imaging after several years. This too
would be consistent with real-life scenarios among patients who might
be lost to follow up [13]. The reality of follow-up even within formal
lung cancer studies suggest that losing patients to follow up with
low-risk lesions does occur.
The current guidelines indicate a change in lung nodule as 2 mm is
considered within the margin of measurement error and significant to
warrant action. Four of the 7 cancers did not meet or marginally met the
required change of 2 mm at the 5-year mark that could be considered
within a margin of error. Although we cannot prove that Subject 4 had a
change of less than 2 mm, if data is interpolated the growth data, it
would not meet the threshold within five years or it would have been
another borderline case. In 2 of our cases, diagnosis was made at 5.5
years and radiographic evidence of change was present at or after the
five-year mark. In one of the cases (Subject 7), while the cancer was not
proven until 6.5 years, change was present at the 5-year mark. If one
were to argue that these cancers were detected at 5 years, we still would
have presented 4 patients (13%) who either lacked definitive change or
were borderline at 5 years and were diagnosed between 93 and 129
months. While one may argue that only two cases represent case failure,
it is important to recognize that the goal of guidelines should create a
safe buffer to diagnose cancer. Therefore, there is reasonable concern
that guidelines need to be extended beyond five years. The significance
of our findings in a case series from routine practice (not part of a clinical
trial) is that growth at 5 years was absent or so minimal in 13% of
diagnosed cancers that it is difficult to determine without a continuing
time horizon of greater than five years and anchoring to the index scan
(the first detection of the GGO).
Additionally, the two cases that represent definitive failure of
guidelines (subject 1 and 2) transformed from pure ground glass to part
solid. This change in characterization which represents 6% of cancers in
our study warrants further consideration as well.
These data suggest that a greater number of lung carcinomas would
be detected upon routine follow-up of GGOs that extended beyond the
current recommendations. Furthermore, the overall survival of the
3
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5. Conclusion
[5]

Based upon our case series, a greater number of lung carcinomas
would be detected upon routine follow up of GGOs if follow up was
extended beyond five years and up to twelve years. Because these can
cers are indolent, it remains unknown whether a higher detection rate
would impact overall survival. Additional long-term studies are war
ranted for greater clarity around this very important issue.

[6]

[7]
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